Partner Aaron Tantleff was quoted in a CIO article, “Privacy Shield review: Prepare for the worst,” about the European Commission’s second annual review of the Privacy Shield data-sharing agreement.
Tantleff said he advises clients to have a backup plan, to adopt another legal basis for data transfers, such as binding corporate rules (BCRs) or model clauses. “I’m advising everyone that’s relying on Privacy Shield to make alternative arrangements, to have a backup plan – not because I suspect Privacy Shield is going to be suspended in the next 30 days but because Privacy Shield will be, in the future, modified or suspended at some point,” he said.
Tantleff said he advises clients to have a backup plan, to adopt another legal basis for data transfers, such as binding corporate rules (BCRs) or model clauses. “I’m advising everyone that’s relying on Privacy Shield to make alternative arrangements, to have a backup plan – not because I suspect Privacy Shield is going to be suspended in the next 30 days but because Privacy Shield will be, in the future, modified or suspended at some point,” he said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”